Suppr超能文献

医疗机构类型和规模对颅咽管瘤治疗和总体生存的影响。

The impact of facility type and volume on treatment and overall survival in craniopharyngioma.

机构信息

Department of Otolaryngology-Head and Neck Surgery, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA, 92868, USA.

Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA.

出版信息

Pituitary. 2023 Dec;26(6):686-695. doi: 10.1007/s11102-023-01359-8. Epub 2023 Oct 17.

Abstract

BACKGROUND

Craniopharyngiomas are uncommon benign sellar and parasellar tumors with high overall survival (OS) and recurrence rates. Treatment is often surgical but may include adjuvant therapies. The impact of adjuvant therapy and surgical approach have been evaluated, however, facility volume and type have not. The purpose of this study is to analyze the influence of facility volume and type on treatment modalities, extent of surgery and survival of craniopharyngioma.

METHODS

The 2004-2016 National Cancer Database (NCDB) was queried for patients diagnosed with craniopharyngioma. Facilities were classified by type (academic vs. non-academic) and low-volume center (LVC) (Treating < 8 patients over the timeline) versus high-volume center (HVC), (Treating ≥ 8 patients over the timeline). Differences in treatment course, outcomes, and OS by facility type were assessed.

RESULTS

3730 patients (51.3% female) with mean age 41.2 ± 22.0 were included with a 5-year estimated OS of 94.8% (94.0-95.5%). 2564 (68.7%) patients were treated at HVC, of which 2142 (83.5%) were treated at academic facilities. Patients treated at HVC's were more likely to undergo both surgery and radiation. Surgical approach at HVC was more likely to be endoscopic. Patients treated at HVC demonstrated significantly higher 5-year OS compared to patients treated at LVC (96% [95% CI 95.6-97.1% versus 91.2% [95% CI 89-92.7%] with lower risk of mortality (Hazard ratio [95% CI] = 0.69 [0.56-0.84]).

CONCLUSION

Treatment of craniopharyngioma at HVC compared to LVC is associated with improved OS, lower 30- and 90-day postoperative mortality risk, and more common use of both radiotherapy and endoscopic surgical approach.

摘要

背景

颅咽管瘤是一种罕见的良性鞍区和鞍旁肿瘤,总生存率(OS)和复发率较高。治疗通常是手术,但可能包括辅助治疗。已经评估了辅助治疗和手术方法的影响,但是,设施数量和类型尚未评估。本研究的目的是分析设施数量和类型对颅咽管瘤治疗方式、手术范围和生存的影响。

方法

2004 年至 2016 年,国家癌症数据库(NCDB)对诊断为颅咽管瘤的患者进行了查询。根据类型(学术型与非学术型)和低容量中心(LVC)(在时间线上治疗<8 例患者)与高容量中心(HVC)对设施进行分类(在时间线上治疗≥8 例患者)。评估了设施类型对治疗过程、结果和 OS 的差异。

结果

共纳入 3730 例(51.3%为女性)患者,平均年龄为 41.2±22.0 岁,5 年估计 OS 为 94.8%(94.0-95.5%)。2564 例(68.7%)患者在 HVC 接受治疗,其中 2142 例(83.5%)在学术设施接受治疗。在 HVC 接受治疗的患者更有可能接受手术和放疗。在 HVC 进行的手术方法更有可能采用内镜。与在 LVC 接受治疗的患者相比,在 HVC 接受治疗的患者的 5 年 OS 显著更高(96%[95%CI 95.6-97.1%]与 91.2%[95%CI 89-92.7%],死亡率风险更低(风险比[95%CI]为 0.69[0.56-0.84])。

结论

与 LVC 相比,在 HVC 治疗颅咽管瘤与 OS 改善、30 天和 90 天术后死亡率风险降低以及更常见的放疗和内镜手术方法的应用有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验